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Abstract
Intra-abdominal candidiasis (IAC) is poorly understood compared to candidemia. We
described the clinical characteristics, microbiology, treatment and outcomes of IAC, and
identified risk factors for mortality. We performed a retrospective study of adults diagnosed
with IAC at our center in 2012–2013. Risk factors for mortality were evaluated using multi-
variable logistic regression. We identified 163 patients with IAC, compared to 161 with can-
didemia. Types of IAC were intra-abdominal abscesses (55%), secondary peritonitis (33%),
primary peritonitis (5%), infected pancreatic necrosis (5%), and cholecystitis/cholangitis
(3%). Eighty-three percent and 66% of secondary peritonitis and abscesses, respectively,
stemmed from gastrointestinal (GI) tract sources. C. albicans (56%) and C. glabrata (24%)
were the most common species. Bacterial co-infections and candidemia occurred in 67%
and 6% of patients, respectively. Seventy-two percent of patients underwent an early
source control intervention (within 5 days) and 72% received early antifungal treatment.
100-day mortality was 28%, and highest with primary (88%) or secondary (40%) peritonitis.
Younger age, abscesses and early source control were independent predictors of survival.
Younger age, abscesses and early antifungal treatment were independently associated
with survival for IAC stemming from GI tract sources. Infectious diseases (ID) consultations
were obtained in only 48% of patients. Consulted patients were significantly more likely to
receive antifungal treatment. IAC is a common disease associated with heterogeneous
manifestations, which result in poor outcomes. All patients should undergo source control
interventions and receive antifungal treatment promptly. It is important for the ID community
to become more engaged in treating IAC.
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Introduction
Invasive Candida infections are the most common non-mucosal fungal diseases among hospi-
talized patients in the developed world. Invasive candidiasis comprises candidemia and deep-
seated candidiasis [1, 2]. Intra-abdominal candidiasis (IAC) is the most common type of deep-
seated candidiasis, but remains poorly understood compared to candidemia [3]. Epidemiologic
reports, antifungal treatment trials and diagnostic studies of invasive candidiasis have focused
largely on candidemia [4]. Research on IAC is limited by the disease’s clinical heterogeneity, a
lack of standardized disease definitions, and difficulties in establishing diagnoses [3, 5, 6].
IAC encompasses a range of disease manifestations, which occur in patients with various
underlying conditions and risk factors involving the gastrointestinal (GI) tract and digestive
system [6, 7]. The clinical significance of Candida in cultures of samples from intra-abdominal
sites is controversial, as mixed infections with bacteria are frequent and the settings in which
antifungal treatment is beneficial are not established conclusively [6, 8]. Clearly, Candida con-
tributes to poor outcomes in some patients with intra-abdominal infections [7, 9]. However,
other patients do well following source control and antibacterial treatment, without receiving
antifungal agents.
Clinical studies of IAC and the development of well-formulated guidelines for its manage-
ment are recognized as pressing priorities [3]. The objectives of this study were to determine
the incidence of IAC compared to candidemia, define clinical characteristics and microbiology
of the disease based on types and anatomic sources of infection, describe treatment and out-
comes with particular attention to identifying risk factors for mortality, and assess the involve-
ment of infectious diseases (ID) physicians in patient care.
Methods
Study design and definitions
We performed a retrospective study of adults diagnosed with IAC at the University of Pitts-
burgh Medical Center-Presbyterian University Hospital (UPMC-PUH) from January 1, 2012
through December 31, 2013. UPMC-PUH is a flagship academic, acute care, adult, medical-
surgical referral, organ transplant and level 1 trauma center. The hospital has 586 acute medi-
cal-surgical and 156 ICU beds. Pediatric, obstetrical and gynecological patients, and most
oncology patients are cared for at sister UPMC hospitals. The study was approved by the Uni-
versity of Pittsburgh Institutional Review Board. Informed consent was not given by partici-
pants for their clinical records to be reviewed. Patient information was anonymized and de-
identified prior to the analysis.
Subjects were identified by reviewing microbiologic cultures that yielded Candida from
intra-abdominal sources. IAC was defined in patients with clinical evidence of intra-abdominal
infection and isolation of Candida in a sample collected from an intra-abdominal site collected
under sterile conditions, in accordance with recently proposed criteria [3, 7]. We excluded
patients whose samples were collected from drains that were in place>24 hours. We included
only the initial episode of infection for each patient. The number of cases of IAC and candide-
mia included patients with the respective disease alone and patients who had both diseases.
Our classification of IAC based on types and anatomic sources of infection is summarized in
Table 1.
The primary end-point was 100-day mortality, which was selected because complications of
IAC may occur several weeks after diagnosis. Recurrent IAC was defined as culture-proven
Candida infection occurring after an apparent resolution of clinical or radiographic findings of
an initial Candida infection. Persistent IAC was defined as infection continuing for48 hours
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after appropriate source control and active antifungal treatment, for which Candida was re-iso-
lated on culture from an intra-abdominal sample. Appropriate source control was defined as
adequate drainage of infected material and surgical correction of the underlying pathology (e.g.
perforation or leak). Active treatment was defined by use of an appropriately dosed antifungal
against an infection that: 1) was caused by an isolate that was susceptible to the agent in vitro
(if testing was performed); 2) was caused by a Candida species that is not intrinsically resistant
to the agent; and 3) occurred in a patient who was not previously exposed to the agent. Com-
munity- and hospital-acquired IAC and septic shock were defined by standard criteria [10, 11].
We defined an intervention as early if performed within 5 days of collecting the first culture-
positive sample for Candida. We used 5 days as a cut-off to allow adequate time for the organ-
ism to grow in culture, and for patient care to be coordinated by the healthcare team.
Statistical analysis
Descriptive statistics were used to summarize the cohort. Associations between categorical var-
iables were analyzed using Pearson’s chi-square test or two-tailed Fisher’s exact test, as appro-
priate. Logistic regression was used to evaluate risk factors for mortality. Odds ratios with 95%
confidence intervals were determined for each risk factor. Factors associated with mortality at
the 0.1 significance level in univariate analysis were entered in the full multivariable model
using a backward stepwise approach. Survival functions were estimated using the Kaplan-
Meier method. STATA/SE software, version 13.1 (StataCorp, College Station, Texas) was used
for statistical analysis.
Table 1. Classification of types of intra-abdominal candidiasis (IAC).
IAC classiﬁcation* Deﬁnition
Primary peritonitis Peritoneal inﬂammation** associated with recovery of
Candida spp., occurring in the absence of an apparent
breach of the GI tract or a pathologic process in a visceral
organ.
Secondary peritonitis stemming from a GI
tract source
Peritoneal Candida infection resulting from a pathologic
process or breach of the GI tract (stomach, small bowel or
colon), such as perforation, surgical leak or trauma.
Intra-abdominal abscess stemming from a GI
tract source
Localized collection of Candida and pus that is walled-off
from healthy tissue, resulting from a pathologic process or
breach of the GI tract. Collections may be identiﬁed by
imaging studies*** or intra-operatively.
Secondary peritonitis stemming from a
hepatobiliary or pancreatic source
Peritoneal Candida infection resulting from a pathologic
process of the liver, gallbladder, biliary or hepatic ducts, or
pancreas.
Intra-abdominal abscess stemming from a
hepatobiliary or pancreatic source
Abscess (as deﬁned above) resulting from a pathologic
process of the liver, gallbladder, biliary or hepatic ducts, or
pancreas. Infected bilomas, pancreatic pseudocysts or
other (peri)pancreatic collections are categorized as
abscesses.
Infected pancreatic necrosis Candida infection of non-vitalized pancreatic tissue
resulting from chronic pancreatitis.
Cholecystitis, cholangitis Candida infection of the gallbladder or biliary tract.
* In the classiﬁcation scheme, sources of peritonitis and abscesses are divided into: a) gastrointestinal (GI)
tract (stomach and intestines), and b) hepatobiliary system (liver, gallbladder, and associated ducts) or
pancreas.
** Peritoneal inﬂammation was deﬁned by neutrophil counts >250/mm3.
*** A majority of patients in this study received computed tomography scans.
doi:10.1371/journal.pone.0153247.t001
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Results
Clinical characteristics of IAC
In 2012–2013, 34,402 patients were admitted to UPMC-PUH. We identified 163 and 161
patients with IAC and candidemia, respectively (rates: 4.7 per 1,000 admissions). Overall, 25%
(40/163) of patients with IAC were immunocompromised, and 53% (87/163) had abdominal
surgery in the preceding 12 months (Table 2); 18% (30/163) presented in septic shock. The
most common types of IAC were intra-abdominal abscesses (55%, 89/163) and secondary peri-
tonitis (33%, 53/163), followed by primary peritonitis (5%, 8/163), infected pancreatic necrosis
(5%, 8/163), and cholecystitis/cholangitis (3%, 5/163). Eighty-three percent (44/53) and 66%
Table 2. Clinical characteristics, treatment and outcomes of patients with intra-abdominal candidiasis (IAC).
Parameter All (n = 163) Primary
peritonitis
(n = 8)
Secondary
peritonitis,
GI tract
source
(n = 44)
Abscess,
GI tract
source
(n = 59)
Secondary
peritonitis,
hepatobiliary/
pancreatic
source (n = 9)
Abscess,
hepatobiliary/
pancreatic
source
(n = 30)
Infected
pancreatic
necrosis
(n = 8)
Cholecystitis,
cholangitis
(n = 5)
P
value
Age, median (range) 59 (21–90) 57 (40–78) 63 (23–90) 61 (23–84) 57 (32–65) 59 (21–88) 45 (26–74) 49 (41–85) 0.69
Male gender 89 (55) 6 (75) 22 (50) 25 (42) 7 (78) 18 (60) 7 (88) 4 (80) 0.06
Race1
White 134/150 (89) 5/6 (83) 34/38 (89) 48/56 (86) 9/9 (100) 27/29 (93) 6/7 (86) 5/5 (100)
Black 13/150 (9) 1/6 (17) 4/38 (11) 6/56 (11) 0/8 1/29 (3) 1/7 (14) 0/5 0.89
Immunocompromised2 40 (25) 2 (25) 11 (25) 12 (20) 7 (78) 8 (27) 0 0 0.01
Solid organ transplant 20 (12) 2 (25) 4 (9) 3 (5) 7 (78) 4 (13) 0 0 <0.001
Obesity (BMI>30) 51 (31) 3 (38) 11 (25) 18 (31) 2 (22) 13 (43) 2 (25) 2 (40) 0.72
Surgery in the
preceding 12 months
87 (53) 1 (13) 19 (43) 42 (71) 7 (78) 14 (47) 1 (13) 3 (60) <0.001
Healthcare-associated
IAC
133 (82) 8 (100) 32 (73) 49 (83) 9 (100) 23 (77) 7 (88) 5 (100) 0.33
Septic shock 30 (18) 4 (50) 9 (20) 8 (14) 3 (33) 2 (7) 3 (38) 1 (20) 0.03
Bacterial co-infection 110 (67) 1 (13) 27 (61) 46 (78) 6 (67) 22 (73) 6 (75) 2 (40) 0.007
C. glabrata infection 43 (26) 1 (13) 17 (39) 13 (22) 2 (22) 7 (23) 1 (13) 2 (40) 0.44
Candidemia3 8/125 (6) 0/6 1/32 (3) 2/44 (5) 2/9 (22) 2/24 (8) 1/7 (14) 0/3 0.34
Type of source control
Surgical 96 (59) 2 (25) 40 (91) 29 (49) 6 (67) 11 (37) 7 (88) 1 (20) <0.001
Percutaneous 59 (36) 04 4 (9) 30 (51) 3 (33) 18 (60) 1 (13) 3 (60) <0.001
Transgastric 2 (1) 0 0 0 0 1 (3) 0 1 (20) 0.04
Antibacterial treatment 161 (99) 8 (100) 43 (98) 58 (98) 9 (100) 30 (100) 8 (100) 5 (100) 1.00
Antifungal treatment
within 5 days
117 (72) 7 (88) 33 (75) 37 (64) 9 (100) 23 (77) 7 (88) 2 (40) 0.15
Recurrence/
persistence
11 (7) 0 2 (5) 6 (10) 2 (22) 1 (3) 0 0 0.44
100-day mortality 46 (28) 7 (88) 15 (34) 11 (19) 6 (67) 4 (13) 2 (25) 1 (20) <0.001
Data are presented as absolute numbers (percentages), unless otherwise indicated.
1 Race was not available for all patients
2 Immunocompromised conditions: solid organ transplant (12%, 20/163), corticosteroid treatment (7%, 11/163), cancer chemotherapy (4%, 7/163), TNF-α
blocker treatment (1%, 2/163)
3 Organisms recovered from blood: C. albicans (4), C. glabrata (2), C. parapsilosis (1), C. krusei (1)
4 Patients with primary peritonitis in the setting of liver cirrhosis underwent diagnostic, rather than therapeutic paracentesis
Abbreviations: GI, gastrointestinal; IAC, intra-abdominal candidiasis
doi:10.1371/journal.pone.0153247.t002
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(59/89) of secondary peritonitis and abscesses, respectively, stemmed from gastrointestinal
(GI) tract sources (Table 2). Clinical characteristics of secondary peritonitis and abscesses are
compared in Table 3.
Microbiology
A total of 180 Candida isolates were recovered (C. albicans 57%, C. glabrata 25%, C. parapsilo-
sis 10%, C. tropicalis 5%, C. krusei 3%, C. rugosa 0.6% and C. utilis 0.6%). Infection with two
Candida species occurred in 10% (17/163) of patients. Antifungal susceptibility testing was
requested on 13% (23/180) of isolates (C. albicans 5, C. glabrata 13, C. parapsilosis 3, C. krusei
1, C. rugosa 1). All C. glabrata were susceptible dose-dependent to fluconazole (MIC range,
8–32 μg/ml); 38% (5/13) of isolates were recovered from patients with azole exposure in the
preceding 3 months. Seventy-seven percent (10/13) and 23% (3/13) of C. glabrata were caspo-
fungin-susceptible and -intermediate (MIC, 0.25 μg/ml), respectively. The latter isolates were
associated with prior drug exposure. Non-C. glabrata isolates were azole- and echinocandin-
susceptible.
Bacterial co-infection was present in 67% (110/163) of patients (S1 Table. Bacteria isolated
in cases of co-infection). Enterococci were most common (29%, 47/163), followed by Escheri-
chia coli (19%, 31/163) and Klebsiella spp. (15%, 24/163). Candidamono-infection was more
likely during primary peritonitis (88%, 7/8) and cholecystitis/cholangitis (80%, 4/5) than other
types of IAC (28%, 42/150; p = 0.001).
C. glabrata was significantly more likely to cause IAC among patients who had two or more
prior abdominal surgeries within the previous year (47%, 14/30 vs. 22%, 29/133; p = 0.007),
Table 3. Comparison of clinical characteristics between patients with secondary peritonitis and intra-abdominal abscess.
Parameter Secondary Peritonitis (n = 53) Abscess (n = 89) P value
Age in years, median (range) 60 (23–90) 59 (21–88) 0.95
Male sex 29 (55) 43 (48) 0.46
Immunocompromised 18 (34) 20 (23) 0.14
Site of origin1
Gastric/Duodenum 10 (19) 16 (18) 0.89
Jejunum/Ileum 19 (36) 12 (14) 0.002
Colon 15 (28) 31 (35) 0.42
Liver/Gallbladder 6 (11) 12 (14) 0.71
Pancreas 3 (6) 17 (19) 0.03
Prior intra-abdominal surgery 26 (49) 56 (63) 0.11
Healthcare-associated IAC 41 (77) 72 (81) 0.61
Septic shock 12 (23) 10 (11) 0.07
Perforation2 29 (55) 42 (47) 0.39
Bacterial co-infection 33 (62) 68 (76) 0.07
C. glabrata infection 19 (36) 20 (23) 0.08
Candidemia 3/4 (7) 4 (6) 1.00
Recurrence/Persistence 4 (8) 7 (8) 1.00
100-day mortality 21 (40) 15 (17) 0.003
Data are presented in absolute numbers (percentages), unless otherwise indicated.
1Site of origin in one female patient with intra-abdominal abscess was the genital tract.
2Rates of Candida infection by site of perforation during the study period were: stomach (39%, 12/31), duodenum (22%, 8/37), jejunum/ileum (25%, 17/
69), colon (19%, 32/172), and appendix (4%, 2/50).
doi:10.1371/journal.pone.0153247.t003
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and to be involved in co-infections with multi-drug resistant (MDR) Gram-negative bacteria
(extended-spectrum beta lactamase-producing or carbapenem-resistant Enterobacteriaecae)
(14%, 6/43 vs. 2%, 2/120; p = 0.005). There were no differences in Candida spp. or rates of bac-
terial co-infection for healthcare-associated vs. community-acquired IAC, anatomic source, or
presence of septic shock. There were trends toward more C. glabrata infections and bacterial
co-infections during secondary peritonitis than in abscesses (p = 0.08 and 0.07, respectively).
At least one set of blood cultures was collected from 125 patients within 10 days of the diag-
nosis of IAC. The rate of candidemia was 6% (8/125). Twenty-four percent (30/125) of patients
with IAC had concomitant bacteremia.
Treatment and outcomes
Overall, 96% (157/163) of patients underwent at least one source control intervention (drain-
age and/or repair of an anatomical defect) to treat IAC. Early interventions (within 5 days of
collecting the first culture-positive sample for Candida) were performed in 72% (118/163) of
patients. Surgical intervention was undertaken in 59% (96/163), percutaneous drainage in 36%
(59/163), and transgastric drainage in 1% (2/163). Reoperation was performed in 21% (20/96)
of patients who underwent a surgical procedure, at median 9 days following the initial inter-
vention (Interquartile range, IQR, 3–15 days). Secondary peritonitis was significantly more
likely to be treated with abdominal surgery than were abscesses (87%, 45/52 vs. 45%, 40/89;
p<0.001). Abscesses were more likely to undergo percutaneous drainage (53%, 48/90 vs. 13%,
7/52; p<0.001).
Ninety-nine percent (161/163) and 77% (125/163) of patients received antibacterial and
antifungal therapy, respectively; 72% (117/163) received antifungal therapy within 5 days.
Median duration of antifungal treatment was 14 days (range, 1–88 days). Early antifungal treat-
ment was more likely among patients with healthcare-associated (75%, 100/133) than commu-
nity-associated IAC (57%, 17/30; p = 0.05). Fifty-eight percent (94/163) of patients were
treated with a single antifungal agent, including fluconazole (50%, 82/163), caspofungin (7%,
11/163) or voriconazole (0.6%, 1/163). Nineteen percent (31/163) of patients were treated with
multiple agents; 29 patients received different agents sequentially, and 2 organ transplant
patients received combination therapy with voriconazole and caspofungin due to concern for
concomitant invasive aspergillosis.
Median length of hospital stay was 14 days after diagnosis of IAC (IQR, 7–26 days). Recur-
rent or persistent IAC occurred in 7% (11/163) of patients (S2 Table. Clinical characteristics of
patients with culture-proven recurrent or persistent intra-abdominal candidiasis), 36% (4/11)
of whom did not receive antifungal treatment initially. C. glabrata was the causative agent in
64% (7/11) of recurrent or persistent cases. The overall 100-day mortality rate was 28% (46/
163), and highest among patients with primary peritonitis (88%, 7/8) and secondary peritonitis
due to hepatobiliary/pancreatic (75%, 6/8) or GI tract sources (34%, 15/44) (Table 1, Fig 1).
The 30-day mortality rate was 20% (32/163).
Younger age, the presence of an abscess and early source control were independently associ-
ated with survival among all patients with IAC (Table 4). There were no significant differences
in mortality among patients with Candidamono-infection or bacterial co-infection, or among
those with or without candidemia. Since IAC most commonly manifested as secondary perito-
nitis or abscesses that stemmed from GI tract sources, we also investigated factors associated
with outcomes in this group (Table 5). Younger age, presence of an abscess and early antifungal
therapy were independently associated with survival.
ID consultation was obtained in 48% (79/163) of patients. Median time to initial consulta-
tion was 2 days from the collection of the first sample that was culture-positive for Candida
Intra-Abdominal Candidiasis and Antifungal Treatment
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(IQR, -2 to +6 days). Consulted patients were more likely to receive antifungal treatment (82%,
65/79 vs. 60%, 50/84; p = 0.002). Forty-eight percent (35/79) of ID consults resulted in initia-
tion of antifungal therapy.
Discussion
Our study is notable for several important findings, beginning with the observation that IAC
was at least as common as candidemia at our center. We demonstrate that IAC encompasses
complex and highly heterogeneous types of infection, which were associated with 100-day
mortality rates that ranged from 13% to 88%. Aggressive management was crucial for
improved outcomes, as source control interventions and antifungal treatment within 5 days
were independently associated with survival among the entire cohort and large subgroups of
patients, respectively. Early antifungal treatment occurred in 72% of patients. In contrast, 99%
of patients received antibiotic treatment, often in the absence of positive bacterial cultures.
Taken together, our findings indicate that IAC is a disease associated with poor outcomes, and
for which ID physicians often are not involved in patient care.
The heterogeneity of IAC poses a formidable hurdle to research. We developed a classifica-
tion scheme based on the types and anatomic sources of infection, which is more precise than
previous efforts to categorize IAC and correlates with patient outcomes [3, 12]. In this scheme,
IAC manifests as primary peritonitis, secondary peritonitis, intra-abdominal abscesses, biliary
Fig 1. Survival analysis by type of intra-abdominal candidiasis.
doi:10.1371/journal.pone.0153247.g001
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infections, or infected pancreatic necrosis. Secondary peritonitis and abscesses, which account
for a significant majority of IAC, are subdivided into infections that stem from either GI tract
or hepatobiliary/pancreatic sources. Previous descriptions of IAC often used the term “second-
ary peritonitis” loosely to refer to both peritonitis and abscesses [3, 5, 13].
Abscesses, regardless of source, were associated with a relative low mortality rate (17%),
whereas primary peritonitis and secondary peritonitis due to hepatobiliary/pancreatic or GI
tract sources carried the highest mortality (88%, 75% and 34%, respectively). Patients with pri-
mary or secondary peritonitis were significantly more likely than patients with abscesses to
have septic shock, a predictor of mortality in several studies [7, 9, 14, 15]. The combined mor-
tality rate of 47% (28/60) for Candida peritonitis fell within the 25%-75% range reported previ-
ously [9, 15–21]. Our overall 100-day and 30-day mortality rates of 28% and 20%, respectively,
were similar to the 27% rate at 30-days in a retrospective, multi-center study of IAC [7].
The finding that early source control was a crucial determinant of survival is consistent with
previous data [7]. At the same time, our experience highlights the challenges in achieving
timely and definitive source control. Twenty-five percent (39/157) of interventions
occurred> 5 days after diagnosis, with delays often due to the severity of disease,
Table 4. Predictors of 100-daymortality for all subjects with IAC.
Parameter Non-survivors*
(n = 46)
Survivors
(n = 117)
Univariate OR
(95% CI)
Univariate P
value
Multivariate OR
(95% CI)
Multivariate P
value
Age, median (interquartile
range)
64 (57–77) 58 (46–67) 1.04 (1.01–1.06) 0.002 1.06 (1.03–1.09) <0.001
Male sex 29 (63) 60 (51) 1.62 (0.80–3.26) 0.18
Solid organ transplant 9 (20) 11 (9) 2.34 (0.90–6.10) 0.08 3.04 (0.98–9.43) 0.054
Obesity (BMI >30) 15 (33) 36 (31) 1.09 (0.52–2.26) 0.82
Healthcare-associated
disease
39 (85) 94 (80) 1.36 (0.54–3.44) 0.51
APACHE II score, mean
(range)
17 (7–29) 15 (3–29) 1.04 (0.96–1.12) 0.32
Septic shock 15 (33) 15 (13) 3.29 (1.45–7.48) 0.004 . . . . . .
Perforation 20 (43) 51 (44) 1.00 (0.50–1.98) 0.99
Presence of abscess 15 (33) 74 (63) 0.28 (0.14–0.58) 0.001 0.25 (0.11–0.57) 0.001
Bacterial co-infection 26 (57) 84 (72) 0.51 (0.25–1.04) 0.06 . . . . . .
C. glabrata infection 11 (24) 32 (27) 0.83 (0.38–1.84) 0.65
Candidemia 3/36 (8) 5/89 (6) 1.53 (0.35–6.76) 0.57
Surgical intervention 26 (57) 70 (60) 0.87 (0.44–1.74) 0.70
Surgical intervention (within
5d)
19 (41) 58 (50) 0.51 (0.23–1.14) 0.34
Source control intervention
(within 5d)
25 (54) 93 (79) 0.38 (0.18–0.76) 0.002 0.23 (0.11–0.57) 0.001
Antifungal treatment (within
5d)
31 (67) 86 (74) 0.74 (0.36–1.56) 0.44
Infectious disease
consultation
21 (46) 58 (50) 0.85 (0.43–1.69) 0.65
Data are presented in absolute numbers (percentages), unless otherwise indicated. Variables in ellipsis were removed from the multivariable analysis
using backward elimination.
*Cause of death: sepsis (20), multi-organ failure (4), heart failure/cardiac event (4), respiratory failure (4), liver failure (2), hemorrhage/ischemia (2),
hospice (7), unknown (3)
Abbreviation: OR, odds ratio.
doi:10.1371/journal.pone.0153247.t004
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complications of prior surgeries and/or lack of distinct foci of infection. Twenty-one percent of
patients who were treated surgically required an additional intervention; 7% of patients were
documented by rigorous criteria to have recurrent or persistent Candida infections. The supe-
rior survival we observed with abscesses likely reflects a greater likelihood of complete extirpa-
tion than with less well-localized infections. Not surprisingly, abscesses were significantly more
likely than secondary peritonitis to be treated with percutaneous drainage, rather than surgical
interventions.
The role of antifungal agents in the treatment of IAC is controversial [6–9, 18, 20, 22–25],
and practice guidelines are conflicting [12, 26, 27]. Moreover, there is ongoing debate about the
clinical significance of Candida recovered from intra-abdominal sites [8]. Therefore, it is nota-
ble that our data and those from a recent study establish the value of timely antifungal treat-
ment in important subgroups of patients with IAC [7]. Mortality for Candidamono-infection
and Candida-bacterial co-infections was comparable in each study, indicating that Candida
spp. are significant pathogens within the abdominal cavity rather than innocent bystanders [8].
While it is clear that some patients with IAC do well without antifungal treatment, our findings
suggest that clinicians are unable to accurately identify these patients. In many regards, the
management of IAC at present resembles that of candidemia in the pre-fluconazole era, when
ad hoc decisions were made about initiating antifungal treatment [28]. After it became appar-
ent that clinicians were unable to accurately select those candidemic patients who required
Table 5. Predictors of 100-daymortality for subjects with IAC stemming from GI tract sources.
Parameter Non-survivors
(n = 26)
Survivors
(n = 77)
Univariate OR
(95% CI)
Univariate P
value
Multivariate OR
(95% CI)
Multivariate P
value
Age, median (interquartile
range)
68 (58–77) 58 (46–68) 1.04 (1.01–1.08) 0.01 1.04 (1.01–1.08) 0.018
Male 15 (58) 32 (42) 1.92 (0.78–4.72) 0.16
Solid organ transplant 3 (12) 4 (5) 2.38 (0.50–11.43) 0.28
Obesity (BMI >30) 11 (42) 18 (23) 21.84 (0.67–5.02) 0.07 . . . . . .
Healthcare-associated
disease
20 (77) 61 (79) 0.87 (0.30–2.54) 0.81
APACHEII score 17 (7–27) 16 (5–29) 1.04 (0.94–1.14) 0.47
Septic shock 6 (23) 11 (14) 1.8 (0.59–5.48) 0.30
Perforation 19 (73) 51 (66) 1.38 (0.52–3.71) 0.52
Presence of abscess 11 (42) 48 (62) 0.44 (0.18–1.09) 0.08 0.36 (0.13–0.96) 0.042
Bacterial co-infection 16 (62) 57 (74) 0.56 (0.22–1.44) 0.23
C. glabrata infection 7 (27) 23 (30) 0.86 (0.32–2.34) 0.78
Candidemia 0/19 3/57 (5) 0.57
Surgical intervention 19 (73) 50 (65) 1.47 (0.55–3.92) 0.45
Surgical intervention (within
5d)
15 (58) 42 (55) 1.55 (0.63–3.81) 0.78
Source control intervention
(within 5d)
17 (65) 63 (82) 0.49 (0.20–1.22) 0.09 . . . . . .
Antifungal treatment (within
5d)
13 (50) 56 (73) 0.38 (0.15–0.94) 0.04 0.36 (0.13–0.96) 0.042
Infectious disease
consultation
6 (23) 28 (36) 0.53 (0.19–1.46) 0.22
Data are presented in absolute numbers (percentages), unless otherwise indicated. Variables in ellipsis were removed from the multivariate analysis using
backward elimination.
Abbreviation: OR, odds ratio.
doi:10.1371/journal.pone.0153247.t005
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treatment, practice guidelines were changed to endorse an antifungal agent for all positive
blood cultures [27, 28]. Likewise, we advocate immediate antifungal treatment for all patients
with intra-abdominal infections in which Candida spp. are recovered from surgical samples or
freshly-placed drains. Current data are insufficient to recommend a preferred agent for treat-
ment of IAC. Several studies of candidemia suggest that time to initiation of treatment may be
a more important determinant of outcome than choice of a specific antifungal [29–31]. In this
regard, blood-based non-culture tests like β-D-glucan and polymerase chain reaction assays,
used judiciously, may advance the management of IAC by diagnosing patients earlier than cul-
tures of intra-abdominal specimens [1, 2, 32].
Carefully-coordinated, multi-disciplinary patient care is essential to improving outcomes
for IAC [3, 6]. A recent editorial calls for interactions between intensivists, surgeons and radiol-
ogists, recognizes a need for standardized antimicrobial stewardship and source control proto-
cols, but does not mention a role for ID practitioners [6]. In this light, the low rate of ID
consultation in our study is perhaps not surprising. Most studies of IAC appear in critical care
or surgical literature, while ID practice and studies on systemic candidiasis have focused largely
on candidemia. In fact, blood cultures were positive for Candida in only 6% of our cases, a find-
ing consistent with 0–32% rates in previous studies [15, 18–20, 32, 33]. We demonstrated an
impact of ID involvement, as antifungal treatment was significantly more likely among patients
who received a consultation. ID physicians were responsible for initiating an antifungal agent
in 48% (35/79) of consults. Consultation was not associated with improved survival, but we
cannot exclude biases in obtaining consults for more difficult cases.
Our finding that 67% of IAC were mixed infections is consistent with reports that bacteria,
in particular enteric pathogens like Enterococcus and Enterobacteriaceae, are recovered with
Candida in most cases [7, 15]. As in other studies, C. albicans was the most common species
[7, 9, 15, 16, 34]. C. glabrata, the second most common species, was notable for significant
associations with multiple prior abdominal surgeries and MDR Gram-negative bacterial co-
infection. C. glabrata candidemia also has been linked to GI tract and biliary sources [35].
Interestingly, 10% of Candida isolates were C. parapsilosis, a species long associated with exog-
enous sources such as intravenous catheters. Emerging microbiome data now indicate that C.
parapsilosis constitutes part of the GI flora in some patients [36].
We recently reported that IAC, in particular cases due to C. glabrata, was a hidden reservoir
for emergence of echinocandin resistance [37]. Along these lines, it is notable that antifungal
susceptibility testing was requested on only 30% of C. glabrata and 13% of all Candida isolates.
One hundred percent and 23% of C. glabrata tested had reduced susceptibility to fluconazole
and caspofungin, respectively. Other centers have reported lower rates of non-susceptibility
during IAC [7], which may reflect differences in patient populations and/or antifungal usage.
Our past and current data suggest that susceptibility testing should be performed routinely
among patients with IAC who have remote or ongoing antifungal exposure [37].
It is important to acknowledge that our results were shaped by practices and populations at
UPMC-PUH. For example, we care for many patients undergoing high-risk GI surgery and
organ transplantation, but few pediatric, obstetrical-gynecological or oncology patients. Expe-
rience at other centers may differ, which highlights the importance of understanding patient
populations, epidemiology, clinical manifestations and outcomes locally. It is also possible that
we missed cases in which intra-abdominal infections were not drained or samples were not cul-
tured. Likewise, the rates of IAC and recurrent or persistent infections were certainly under-
estimated due to the rigorous definitions used in this study. Our ability to draw conclusions
about certain IAC types (such as primary peritonitis, infected pancreatic necrosis and cholecys-
titis/cholangitis) was limited by the small number of cases. Thus, care in interpreting compari-
sons between IAC subgroups is warranted. Lastly, our study design precluded us from
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identifying risk factors for IAC, describing rates of disease among patients with various predis-
posing conditions, accurately determining the start date of infections, or assessing the efficacy
of pre-emptive antifungal treatment among high-risk patients.
Further studies of IAC are needed to corroborate and expand upon our findings. Recent
papers demonstrate that multicenter studies of deep-seated candidiasis are feasible, even
among complex surgical patients [6, 7, 38]. Given the heterogeneity of IAC, studies should
focus on well-defined subgroups of patients that share disease manifestations or predisposing
conditions [6]. In this regard, our classification scheme (or variations) may be useful. At the
same time, there is need for more research on the pathogenesis of IAC. Recently-developed
mouse models of IAC demonstrated that C. albicans and C. glabrata gene expression and path-
ogenic mechanisms differed from those of hematogenous candidiasis [39, 40]. Animal models
and other experimental systems are also powerful tools for studying diagnostics, antifungal
treatment and emergence of resistance, in the absence of clinical trial data [3]. Finally, ID spe-
cialists have important roles to play in the management of IAC by guiding antifungal treat-
ment, interpreting antifungal susceptibility patterns, integrating non-culture diagnostic tests
into patient care, and designing stewardship protocols and research studies. It is incumbent
upon the ID community to become more actively engaged in patient care and research into the
disease.
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